Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

August 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Posaconazole: An aid against fungal infections

MAOA and CDH13: The “serial-killer genes”

Analysis of new species of Listeria improves food safety

Posaconazole: An aid against fungal infections
  • BiotechToday
  • World

Posaconazole: An aid against fungal infections

bioxone May 26, 2021May 25, 2021

Saptaparna Pal, Amity University Kolkata

Posaconazole is the latest antifungal agent to be approved for use in Canada against severe fungal infections. With excellent and intensive activity against a large spectrum of fungi as well as yeasts, as well as having a well-formulated oral formulation, posaconazole provides many possible advantages.

Amphotericin B, whether in lipid-based or deoxycholate formulation, is an endovenous medication with the most versatile spectrum of activity of any antifungal agent. Although, its use is accelerated with a high rate of infusion reactions and nephrotoxicity; the intensifying fungal disease has occurred in patients who were not able to complete treatment. Similar to all triazoles, posaconazole restricts the fungal lanosterol 14 alpha- demethylase enzyme(CYP51), a new member of the cytochrome P450 family. As a result, posaconazole blocks the synthesis of ergosterol, the basic sterol in the fungal cell membrane integrity, and a crucial determinant of cell membrane integrity membrane-associated protein function and progression through the cell cycle.

Posaconazole is administered as an oral suspension at a dose of about 800mg per day; no parenteral formulation is recently available. As, high-fat meals, nutritional supplements and frequent administration all three supports the absorption of posaconazole, the 800mg dose is divided twice daily if the patient is intaking enteral nutrition, and four times daily if not. In the case of fasting individually, the most common steady-state plasma cone is 0.5mg/L based on four times daily dosing, it is a bit higher at 0.72mg/L  when taken twice daily with a high-fat meal or nutritional supplement. Posaconazole has also shown to be at least as effective as Amphotericin B in the case of human blood trials for IFS and murine. Posaconazole is one of the recent remedies against mucormycosis and zygomycosis. Posaconazole is also more active in vitro against a wide range of filamentous fungi than in voriconazole. Posaconazole has a half-life of 35 h and is removed unchanged through the gastrointestinal tract. Because the kidneys play a short role in the excretion of posaconazole, no dose adjustment is necessary, even in cases of severe renal impairment. Posaconazole restricts the hepatic CYP3A4 enzyme, a member of the cytochrome P450 enzyme system; therefore, it may increase the serum concentrations of drugs with which it is coadministered, including tacrolimus and cyclosporine.

Despite the diverse spectrum of activity indicated by in vitro and in vivo experimental data, posaconazole has got Canadian approval only for the treatment of OPC and refractory invasive aspergillus, as well as for the prophylaxis of invasive aspergillus and also candidiasis in high-risk patients. Posaconazole is now the recommended and accepted prophylactic regimen for use in high-risk patients, but its cost may restrict its use.  In terms of other IFIs, along with its tolerated oral formulation and few drug interactions, posaconazole may become the agent of choice for long-term aid of the opportunistic mycoses against which voriconazole has restricted activity, including mucormycosis. However, the high barrier to the resistance created by posaconazole’s unique structure may confirm its niche in treating polyene, -echinocandin, and even triazole resistance IFIs. 

Also read: LOXHD1: A gene crucial for understanding hereditary deafness

References: Page, Andrea V, and W Conrad Liles. “Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.” The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale vol. 19, 4 (2008): 297-305. doi:http://10.1155/2008/825901

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Amphotericin B Aspergillosis Candidiasis Cyclosporine Echinocandin IFIs mucormycosis OPC Posaconazole Triazole Voriconazole Zygomycosis

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Analysis of new species of Listeria improves food safety

bioxone May 27, 2021

Sagnik Nag, Amity University, Kolkata Listeria is a gram-positive bacterial intracellular parasite that causes Listeriosis i.e. a foodborne infection causing fever, muscle aches, and, in many people, diarrhoea. It can cause fatal illness during pregnancy and affect newborns, adults with weakened immune systems and the elderly. According to statistics, 1,700 people in the U.S. get […]

Listeria

Related Post

  • BiotechToday
  • World

Polyphenol metabolism in anoxic soil decoded

bioxone July 1, 2021June 30, 2021

Akash Singh, Banaras Hindu University In soil ecosystems, microorganisms play an important role in controlling organic matter breakdown and nutrient cycling. According to the enzyme latch hypothesis, under saturated water table conditions, the activity of oxidative enzymes (e.g. polyphenols) is suppressed due to a lack of oxygen (O2) as a necessary reactant, resulting in an […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Chronic lung diseases patients are “primed” for severe Coronavirus infections

bioxone July 28, 2021July 27, 2021

Richa Prakash, MSc, Central University of Punjab The whole globe is aware of SARS-CoV-2 as it has infected tens of millions of people worldwide in the first nine months of 2020 making it a deadly pandemic. Along with other comorbidities, people with a history of chronic lung diseases (CLDs) like chronic obstructive pulmonary disease (COPD) […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Role of ERα signalling in Mammary Gland Morphogenesis

bioxone June 24, 2021June 24, 2021

Akash Singh, Banaras Hindu University The mammary gland is an ectodermal exocrine gland whose major job is to generate milk for offspring’s sustenance. Mammary gland morphogenesis begins during the embryonic phase in humans and most mammals, but the most essential component of mammary growth and remodelling happens after birth, during puberty, pregnancy, breastfeeding, and involution. […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy